Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
ApexOnco Front Page
Recent articles
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
